Role of PRMT1 and PRMT5 in Breast Cancer - CRCL-Résistance hormonale, méthylation et cancer du sein
Journal Articles International Journal of Molecular Sciences Year : 2024

Role of PRMT1 and PRMT5 in Breast Cancer

Abstract

Breast cancer is the most common cancer diagnosed in women worldwide. Early-stage breast cancer is curable in ~70-80% of patients, while advanced metastatic breast cancer is considered incurable with current therapies. Breast cancer is a highly heterogeneous disease categorized into three main subtypes based on key markers orientating specific treatment strategies for each subtype. The complexity of breast carcinogenesis is often associated with epigenetic modification regulating different signaling pathways, involved in breast tumor initiation and progression, particularly by the methylation of arginine residues. Protein arginine methyltransferases (PRMT1-9) have emerged, through their ability to methylate histones and non-histone substrates, as essential regulators of cancers. Here, we present an updated overview of the mechanisms by which PRMT1 and PRMT5, two major members of the PRMT family, control important signaling pathways impacting breast tumorigenesis, highlighting them as putative therapeutic targets.

Fichier principal
Vignette du fichier
ijms-25-08854.pdf (2.38 Mo) Télécharger le fichier
Origin Publisher files allowed on an open archive

Dates and versions

hal-04765663 , version 1 (04-11-2024)

Identifiers

Cite

Sébastien Martinez, Stéphanie Sentis, Coralie Poulard, Olivier Trédan, Muriel Le Romancer. Role of PRMT1 and PRMT5 in Breast Cancer. International Journal of Molecular Sciences, 2024, 25, ⟨10.3390/ijms25168854⟩. ⟨hal-04765663⟩
41 View
4 Download

Altmetric

Share

More